Better Information, Better Decisions

New advanced prostate cancer tests lead to better informed treatment plans.


Get more insights about prostate cancer, whether you are assessing your risk beyond the PSA test or treating prostate cancer.


Use state-of-the-art biomarker tests to inform treatment recommendations for your patients.

What are new advanced prostate cancer tests in 2023?

Prostate cancer biomarker tests provide more insights about prostate cancer risk beyond the traditional PSA test.

New advanced prostate cancer tests in 2023 can alleviate worry and provide more information about prostate cancer treatment. A high PSA test doesn’t always tell the entire story or warrant a biopsy right away.

Advanced prostate cancer tests are also known as prostate cancer markers (PCMs) or prostate biomarker tests. There are different tests based on where someone is on their prostate cancer journey. With the right test at the right time, patients and their healthcare providers can better identify risk, prognosis, treatment and next steps. Advanced prostate cancer tests in 2023 are non-invasive and can lead to better plans of action for tackling prostate cancer.

Learn More

Stay up-to-date with the latest prostate cancer news with the links below.

image of a doctor and patient discussing the first study to look into prostate cancer in transgender women.

Transgender Women at Risk for Prostate Cancer

A new study published in the Journal of the American Medical Association (JAMA) analyzed 22 years of data and found 14 prostate cancer cases per 10,000 transgender women. While a small study, it's the first that looks at transgender women.

Man learning about the Decipher RP prostate cancer marker test.

Learn the PCMs Right for You

Take this interactive quiz to learn which advanced prostate cancer biomarker tests are right for you, whether you are deciding if you need to be screened or you want more insights into your diagnosis and treatment plan.

3d rendered illustration of the anatomy of a cancer cell

New Prostate Cancer Marker Identified

Swedish researchers have identified specific proteins in the transforming growth factor beta (TGF-β) signalling pathway, which is a significant path that affects how prostate cancer cells grow and spread. The discovery may make it easier to identify men who are at risk of developing aggressive and life-threatening prostate cancer.